Differences in clinician understanding and management of early menopause after breast cancer

References

• Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365–70
   PubMed Web of Science ®Google Scholar
• Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns and behavioral health outcomes in younger breast cancer survivors: A systematic review. J Natl Cancer Inst 2012;104:386–405
   PubMed Web of Science ®Google Scholar
• Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008;19:1669–80
   PubMed Web of Science ®Google Scholar
• Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 2003;21:4184–93
   PubMed Web of Science ®Google Scholar
• Fellowes D, Fallowfield LJ, Saunders CM, Houghton J. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments? Breast Cancer Res Treat 2001;66:73–81
   PubMed Web of Science ®Google Scholar
• Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769–79
   PubMed Web of Science ®Google Scholar
• WHO Research on the Menopause in the 1990s: Report of a WHO Scientific Group. WHO Technical Report Series No 866. Geneva: World Health Organization, 1996:12–14
   Google Scholar
• Saunders C, Emery L, Hickey M. New direction for multidisciplinary care: Menopausal Symptoms After Cancer Service. Cancer Forum 2010;34:27–30
   Google Scholar
• Colditz GA. Menopausal hormone therapy after breast cancer. Breast Cancer Res 2005;7:168–70
   PubMed Web of Science ®Google Scholar
• Cruickshank S, Hume A, Alder EM. An exploration of the management of menopausal symptoms for women with a diagnosis of breast cancer: lay and professional experiences and expectations. Breast Cancer Research 2008;10:82
   Google Scholar
• Cussons AJ, Stuckey BG, Walsh JP, Burke V, Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clin Endocrinol (Oxf) 2005;62:289–95
   PubMed Web of Science ®Google Scholar
• Sayakhot P, Vincent A, Deeks A, Teede H. Potential adverse impact of ovariectomy on physical and psychological function of younger women with breast cancer. Menopause 2011;18: 786–93
   PubMed Web of Science ®Google Scholar
• Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990;53: 804–10
   PubMed Web of Science ®Google Scholar
• Ortmann O, Pagani O, Jones A, et al. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treat Rev 2011; 37:97–104
   PubMed Web of Science ®Google Scholar
• Burger HG. Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition – an analysis of FSH, oestradiol and inhibin. Eur J Endocrinol 1994; 130:38–42
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351–8
   PubMed Web of Science ®Google Scholar
• Hickey M, Emery LI, Gregson J, Doherty DA, Saunders CM. The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care. Menopause 2010;17: 727–33
   PubMed Web of Science ®Google Scholar
• Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; CD002978
   Google Scholar
• Col N, Kim J, Chlebowski R. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 2005;7:R535–40
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart J-M, et al. Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–46
   PubMed Web of Science ®Google Scholar
• Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453–5
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057–71
   PubMed Web of Science ®Google Scholar
• Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010;CD004923
   Google Scholar
• Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278–83
   PubMed Web of Science ®Google Scholar
• Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147–52
   PubMed Web of Science ®Google Scholar
• Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693
   PubMed Web of Science ®Google Scholar
• Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. Climacteric 2007;10:23–6
   PubMed Web of Science ®Google Scholar
• Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol 2003;21:1660–8
   PubMed Web of Science ®Google Scholar
• Sandhu H, Adams A, Singleton L, Clark-Carter D, Kidd J. The impact of gender dyads on doctor–patient communication: a systematic review. Patient Educ Couns 2009;76:348–55
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997–2008
   PubMed Web of Science ®Google Scholar
• Loi S, Milne RL, Friedlander ML, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1686–91
   PubMed Web of Science ®Google Scholar
• Nissen MJ, Shapiro A, Swenson KK. Changes in weight and body composition in women receiving chemotherapy for breast cancer. Clin Breast Cancer 2011;11:52–60
   PubMed Web of Science ®Google Scholar
• Walsh R. Lifestyle and mental health. Am Psychol 2011;66: 579–92
   PubMed Web of Science ®Google Scholar
• AIHW. Medical labour force 2008. Cat. no. AUS 131. Canberra: AIHW, 2010. Accessed 5 July 2011. Available from: http://www.aihw.gov.au/publication-detail/?id = 6442468395
   Google Scholar